HK1120444A1 - 通過抑制補體的活動延長同種移植物的存活 - Google Patents

通過抑制補體的活動延長同種移植物的存活

Info

Publication number
HK1120444A1
HK1120444A1 HK09101244.3A HK09101244A HK1120444A1 HK 1120444 A1 HK1120444 A1 HK 1120444A1 HK 09101244 A HK09101244 A HK 09101244A HK 1120444 A1 HK1120444 A1 HK 1120444A1
Authority
HK
Hong Kong
Prior art keywords
allograft
prolongation
survival
complement activity
inhibiting complement
Prior art date
Application number
HK09101244.3A
Other languages
English (en)
Inventor
Russell P Rother
Hao Wang
Zhen Zhong
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1120444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of HK1120444A1 publication Critical patent/HK1120444A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09101244.3A 2006-03-02 2009-02-11 通過抑制補體的活動延長同種移植物的存活 HK1120444A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
PCT/US2007/005290 WO2007103134A2 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity

Publications (1)

Publication Number Publication Date
HK1120444A1 true HK1120444A1 (zh) 2009-04-03

Family

ID=38475394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101244.3A HK1120444A1 (zh) 2006-03-02 2009-02-11 通過抑制補體的活動延長同種移植物的存活

Country Status (22)

Country Link
US (1) US20100135992A1 (zh)
EP (2) EP1988882B1 (zh)
JP (2) JP5722524B2 (zh)
KR (2) KR101527225B1 (zh)
CN (1) CN101437501B (zh)
AU (1) AU2007224250B2 (zh)
BR (1) BRPI0708424A2 (zh)
CA (1) CA2644020C (zh)
DK (1) DK1988882T3 (zh)
ES (1) ES2530637T3 (zh)
HK (1) HK1120444A1 (zh)
HR (1) HRP20150182T1 (zh)
IL (1) IL193623A0 (zh)
MX (1) MX2008011054A (zh)
NZ (1) NZ570802A (zh)
PL (1) PL1988882T3 (zh)
PT (1) PT1988882E (zh)
RS (1) RS53864B1 (zh)
RU (1) RU2445975C2 (zh)
SG (1) SG171578A1 (zh)
SI (1) SI1988882T1 (zh)
WO (1) WO2007103134A2 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP2913342A1 (en) * 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Compositions for use in the treatment of antibody mediated neuropathies
JP2010505946A (ja) 2006-10-10 2010-02-25 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 神経再生改善のための補体阻害
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
ES2940466T3 (es) * 2008-11-10 2023-05-08 Alexion Pharma Inc Métodos y composiciones para tratar trastornos asociados al complemento
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
AU2010264520A1 (en) * 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
ME01699B (me) * 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
CN101621801B (zh) * 2009-08-11 2012-11-28 华为终端有限公司 无线局域网的认证方法、***及服务器、终端
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
AU2012256281B2 (en) * 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
WO2015023972A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN113045650A (zh) 2014-12-19 2021-06-29 中外制药株式会社 抗-c5抗体及使用方法
WO2017075325A1 (en) * 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
CR20180364A (es) * 2015-12-18 2018-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos de uso
CN109310759A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 用于在移植排斥治疗中使用的特斯多鲁单抗
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
JP7102353B2 (ja) 2016-06-14 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃ５抗体及びそれらの使用
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
DK3658184T3 (da) 2017-07-27 2023-11-27 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2021146471A2 (en) * 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞***移植调控补体活化作用的体系

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
AU746825B2 (en) * 1998-02-04 2002-05-02 Brigham And Women's Hospital Costimulatory blockade and mixed chimerism in allotransplantation
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) * 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
ATE424893T1 (de) * 2001-06-08 2009-03-15 Novartis Pharma Gmbh Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
ES2283594T5 (es) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
SI1755674T1 (sl) * 2004-05-14 2015-04-30 Alexion Pharmaceuticals, Inc. Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa
CN1980649A (zh) * 2004-05-17 2007-06-13 康宾纳特克斯公司 治疗免疫炎性疾病的方法和试药

Also Published As

Publication number Publication date
NZ570802A (en) 2012-03-30
AU2007224250B2 (en) 2012-05-03
SG171578A1 (en) 2011-06-29
CA2644020A1 (en) 2007-09-13
KR101527225B1 (ko) 2015-06-08
IL193623A0 (en) 2009-08-03
EP1988882B1 (en) 2014-12-17
JP5722524B2 (ja) 2015-05-20
EP1988882A2 (en) 2008-11-12
PL1988882T3 (pl) 2015-04-30
ES2530637T3 (es) 2015-03-04
MX2008011054A (es) 2009-03-03
JP2013155202A (ja) 2013-08-15
PT1988882E (pt) 2015-02-17
WO2007103134A3 (en) 2008-09-12
EP2918269A1 (en) 2015-09-16
SI1988882T1 (sl) 2015-07-31
RU2008139118A (ru) 2010-04-10
KR20080098543A (ko) 2008-11-10
WO2007103134A2 (en) 2007-09-13
CN101437501B (zh) 2012-09-05
BRPI0708424A2 (pt) 2011-05-31
DK1988882T3 (en) 2015-02-23
JP2009528369A (ja) 2009-08-06
KR101650264B1 (ko) 2016-08-22
RS53864B1 (en) 2015-08-31
US20100135992A1 (en) 2010-06-03
CA2644020C (en) 2016-05-10
AU2007224250A1 (en) 2007-09-13
CN101437501A (zh) 2009-05-20
KR20140124023A (ko) 2014-10-23
RU2445975C2 (ru) 2012-03-27
HRP20150182T1 (hr) 2015-06-05

Similar Documents

Publication Publication Date Title
IL193623A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL179240A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
HRP20180611T1 (hr) Postupci smanjenja razina bazofila
EP2173353A4 (en) grafts
IL217452A0 (en) Distributed jammer system
GB0616999D0 (en) Annular mesh
ZA200809941B (en) 2-anilino-4-(heterocyclic)amino-pyrimidines
HK1132268A1 (en) Novel anxiolytic compounds
EP2192904A4 (en) METHODS OF INHIBITING TGF-
GB0604944D0 (en) Pyrrolopyrimidine compounds
GB0618588D0 (en) Fairing
AU2011236106B2 (en) Prolongation of survival of an allograft by inhibiting complement activity
EP2100507A4 (en) SUBSTANCE THAT IS CAPABLE OF INHIBITING CYTOKININE SIGNALING.
TWM292273U (en) Wall-mount type aquarium
AU2007322610B2 (en) Substance capable of inhibiting cytokinin signaling
GB0610696D0 (en) Improved chamber
PL115882U1 (en) Isolating shield
GB0701068D0 (en) Suppression
TWM301006U (en) Slide structure of drawer
IL174888A0 (en) Distributed jammer system
TWM311768U (en) Improved structure of A-ladder
ZA200903302B (en) Substance capable of inhibiting cytokinin signaling
IL182382A0 (en) Distributed jammer system
TWM299072U (en) Improved form structure for underwater granulation
GB0617789D0 (en) Pyrrolopyrimidine compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190305